Table Of Content

SUGIECT (HOE. 196: Vt 46. Bos. -6 & Professional Training, 248 American Cancer Society Fourth National Acute iymphocytic leukemia Conference on Cancer Nursing Research, 342 Bone marrow transplantation, 152-153 American Cancer Society National Conference on Acute myeloid leukemia Cancer Prevention and Early Detection, 64 Bone marrow transplantation, 152 American Cancer Society Scholarships in Cancer Nursing, 28 Adenocarcinoma International Union Against Cancer (UICC) Bladder cancer, 93-94 Cancer Management Meeting, 302, 375 African Americans. See also Minority groups Sixth Biennial Symposium on Minorities, Cancer statistics, 113-125, 164 (Errata) the Medically Underserved, and Cancer, 375 Alcohol Antibiotic therapy Nutrition, 330-332 Pulmonary complications, 307-308, 311 The Prevention of Occupational Cancer, 68 Antiemetics (Guest Editorial) Systemic treatments, 135 Allogenic marrow transplantation Antisense strategies Stem cell sources, 144-145 Systemic treatments, 135 American Cancer Society Asbestos Cancer Nursing Scholarships, 28 Ashestos-related cancer, 254-256 (Letter) Extramural Grants Program for Research and Health The Prevention of Occupational Cancer, 68 Professional Training, 248 (Guest Editorial) Guidelines on Diet, Nutrition, and Cancer Prevention: Reducing the Risk of Cancer with Healthy Food Atypical (non-tuberculosis) mycobacteria Choices and Physical Activity, 325-341 Pulmonary complications, 309 Highlights of National Conference on Cancer Autologous marrow transplantation Prevention and Early Detection, 246-247 Stem cell sources, 145 Highlights of National Conference on Colorectal Cancer, 45 Autolymphocyte therapy International Union Against Cancer On-Line Renal cell carcinoma, 295-296 Information Resources, 92 National Conference on Cancer Nursing Research, 141 National Conference on Cancer Prevention and Early Detection, 64 Bladder cancer, 97, 98, 100 Analytic epidemiology Malignant melanoma, vaccine therapy, 229 Occupational cancer, 82-85 Renal cell carcinoma, 293 Anaplastic thyroid carcinoma Bacterial pneumonia infections Molecular pathogenesis, 268-269. See also Thyroid Pulmonary complications, 306-308 carcinoma Bacterial toxins Androgens Systemic treatments, 140 Hormone replacement therapy, 347-348 Bladder cancer, 93-112 Anemia Adjuvant or neoadjuvant chemotherapy, 107-108 Hematopoietic growth factors, 175-176 Clinical features, 95-96 Angiosarcoma of liver Diagnosis, 96 Occupational cancer, 81 Epidemiology and etiology, 93-95 Overview, 93 Aniridia The Prevention of Occupational Cancer, 68 Wilms tumor, 47 (Guest Editorial) Announcements Treatment of metastatic disease, 104-107 American Association for Cancer Research 1996 Treatment of muscle-invasive, 102-104 Research Fellowships, 63 Treatment of superficial, 96-102 American Association for Cancer Research 1997 Bone marrow transplantation, 142-164 Research Fellowships and Gertrude Elion Cancer Acute lymphocytic leukemia, 152-153 Research Award, 373 Acute myeloid leukemia, 152 American Cancer Society and International Union Biologic aspects, 143-144 Against Cancer On-Line Information Breast cancer, 156 Resources, 92 Cancer Therapy — The 21st Century, 131 American Cancer Society Extramural Grants (Guest Editorial) Program for Research and Health Chronic lymphocytic leukemia, 154 376 CA—A CANCER JOURNAL FOR CLINICIANS SUGIECT (HOE. 196: Vt 46. Bos. -6 & Professional Training, 248 American Cancer Society Fourth National Acute iymphocytic leukemia Conference on Cancer Nursing Research, 342 Bone marrow transplantation, 152-153 American Cancer Society National Conference on Acute myeloid leukemia Cancer Prevention and Early Detection, 64 Bone marrow transplantation, 152 American Cancer Society Scholarships in Cancer Nursing, 28 Adenocarcinoma International Union Against Cancer (UICC) Bladder cancer, 93-94 Cancer Management Meeting, 302, 375 African Americans. See also Minority groups Sixth Biennial Symposium on Minorities, Cancer statistics, 113-125, 164 (Errata) the Medically Underserved, and Cancer, 375 Alcohol Antibiotic therapy Nutrition, 330-332 Pulmonary complications, 307-308, 311 The Prevention of Occupational Cancer, 68 Antiemetics (Guest Editorial) Systemic treatments, 135 Allogenic marrow transplantation Antisense strategies Stem cell sources, 144-145 Systemic treatments, 135 American Cancer Society Asbestos Cancer Nursing Scholarships, 28 Ashestos-related cancer, 254-256 (Letter) Extramural Grants Program for Research and Health The Prevention of Occupational Cancer, 68 Professional Training, 248 (Guest Editorial) Guidelines on Diet, Nutrition, and Cancer Prevention: Reducing the Risk of Cancer with Healthy Food Atypical (non-tuberculosis) mycobacteria Choices and Physical Activity, 325-341 Pulmonary complications, 309 Highlights of National Conference on Cancer Autologous marrow transplantation Prevention and Early Detection, 246-247 Stem cell sources, 145 Highlights of National Conference on Colorectal Cancer, 45 Autolymphocyte therapy International Union Against Cancer On-Line Renal cell carcinoma, 295-296 Information Resources, 92 National Conference on Cancer Nursing Research, 141 National Conference on Cancer Prevention and Early Detection, 64 Bladder cancer, 97, 98, 100 Analytic epidemiology Malignant melanoma, vaccine therapy, 229 Occupational cancer, 82-85 Renal cell carcinoma, 293 Anaplastic thyroid carcinoma Bacterial pneumonia infections Molecular pathogenesis, 268-269. See also Thyroid Pulmonary complications, 306-308 carcinoma Bacterial toxins Androgens Systemic treatments, 140 Hormone replacement therapy, 347-348 Bladder cancer, 93-112 Anemia Adjuvant or neoadjuvant chemotherapy, 107-108 Hematopoietic growth factors, 175-176 Clinical features, 95-96 Angiosarcoma of liver Diagnosis, 96 Occupational cancer, 81 Epidemiology and etiology, 93-95 Overview, 93 Aniridia The Prevention of Occupational Cancer, 68 Wilms tumor, 47 (Guest Editorial) Announcements Treatment of metastatic disease, 104-107 American Association for Cancer Research 1996 Treatment of muscle-invasive, 102-104 Research Fellowships, 63 Treatment of superficial, 96-102 American Association for Cancer Research 1997 Bone marrow transplantation, 142-164 Research Fellowships and Gertrude Elion Cancer Acute lymphocytic leukemia, 152-153 Research Award, 373 Acute myeloid leukemia, 152 American Cancer Society and International Union Biologic aspects, 143-144 Against Cancer On-Line Information Breast cancer, 156 Resources, 92 Cancer Therapy — The 21st Century, 131 American Cancer Society Extramural Grants (Guest Editorial) Program for Research and Health Chronic lymphocytic leukemia, 154 376 CA—A CANCER JOURNAL FOR CLINICIANS SUBJECT ENDEX: 1996: VOL 46. NOS. 1-6 Chronic myelogenous leukemia, 153-154 Chemotherapy Complications, 148-152, 317 Bladder cancer, 97-98, 102-103, 107-108 Engraftment, 148 Bladder cancer metastatic disease, 104-107 Historical aspects, 142-143 Bone marrow transplantation, 146 Hodgkin’s disease, 155 Cancer Therapy — The 21st Century, 131-133 Marrow collection and infusion, 146-148 (Guest Editorial) Multiple myeloma, 155 Hematopoietic growth factors, 165-184. See also Myelodysplastic syndrome, 153 Hematopoietic growth factors Neuroblastoma, 155-156 Malignant melanoma, vaccine therapy, 228-230, 233 New approaches, 156-157 Occupational cancer, 77 Non-Hodgkin’s lymphoma, 154-155 Pulmonary complications, 315-317 Overview, 142 Renal cell carcinoma, 292-294 Preparative regimens, 146 Systemic treatments, 134-141 Pulmonary complications, 317 Thyroid carcinoma, 279 Stem cell sources, 144-146 Wilms tumor, 53-56 Systemic treatments, 134 Testicular cancer, 156 Childhood cancer Electromagneftiiecl d exposure, 31, 34, 36, 37-41 Brachytherapy Wilms tumor, 46-63. See also Wilms tumor Prostate cancer, 249-253 Cholesterol Brain cancer Estrogen replacement therapy, 344 Electromagnetic field exposure, 31, 34, 37, 40, 41, 42 Nutrition, 334 Breast cancer Progestin replacement therapy, 347 Bone marrow transplantation, 156 Chronic lymphocytic leukemia Cancer Statistics: A Measure of Progress, 4 Bone marrow transplantation, 154 (Guest Editorial) Electromagnetic fielde xposure, 31, 37, 42 Chronic myelogenous leukemia Hematopoietic growth factors, 174 Bone marrow transplantation, 153-154 Hormone replacement therapy, 349-3. Cigarette smoking. See Tobacco Hormone replacement therapy risk, 365-370 The National Cancer Data Base clinical highlights, 191 Clear cell sarcoma of the kidney Nutrition, 332 Wilms tumor, 50, 52, 58 Systemic treatments, 135 Clinical images Bronchiolitis obliterans with organizing pneumonia Malignant melanoma, 245 Pulmonary complications, 318 Colorectal cancer Highlights of American Cancer Society National Cc Conference, 45 The National Cancer Data Base clinical highlights, 190 Cancer statistics, 3-27 Nutrition, 332 African Americans, 113-125, 164 (Errata) Age level, 13, 14, 15, 16-17, 118, 119 Complications. See also Pulmonary complications Cancer Statistics: A Measure of Progress, 3-4 Bone marrow transplantation, 148-152 (Guest Editorial) Hematopoietic growth factors, 175-179 Data limitations, 7 Prostate cancer, 252-253 Global view, 7, 26-27 Pulmonary, 303-320 Incidence, 5-6, 121, 122, 123 Wilms tumor, treatment sequelae, 57, 59 Minority groups, 6, 20, 21, 113-125, 164 (Errata) Cytokines Mortality, 6, 9, 11, 12, 14, 15, 16-17, 18, 19, 20, 24, 118, Renal cell carcinoma, 293-295 119, 120, 122 Pediatric, 24, 25 Systemic treatments, 135 Probability estimates, 6, 8, 10, 12, 13, 121, 122, 123 Stage at diagnosis, 22, 23, 124 D Survival rates, 6-7, 21, 23, 25 Cardiovascular system DETOX Estrogen replacement therapy, 343-346 Malignant melanoma, vaccine therapy, 229, 233 Progestin replacement therapy, 346-347 Diet. See also Nutrition Cervical cancer Cancer Statistics: A Measure of Progress, 3 Cancer Therapy — The 21st Century, 131-132 (Guest Editorial) (Guest Editorial) Guidelines on Diet, Nutrition, and Cancer Prevention: The National Cancer Data Base clinical Reducing the Risk of Cancer with Healthy Food highlights, 192 Choices and Physical Activity, 325-341 VOL. 46 NO. 6 NOVEMBER/DECEMBER 1996 SOR PEG T InN Dex Lo 36 VOl 46 NOS Dietary supplements Epidemiology Nutrition, 337 Bladder cancer, 93-95 Hormone replacement therapy risk, 366-368 Diethylstilbestrol Malignant Melanoma: Perspectives on Incidence and Hormone replacement therapy risk, 367 Its Effects on Awareness, Diagnosis, and Diffuse pulmonary hemorrhage Treatment, 195-198 (Guest Editorial) Pulmonary complications, 317-318 Nutrition, 338 Occupational cancer, 77, 80-89 Drug administration Wilms tumor, 46-47 Systemic treatments, 134 Errata Cancer statistics for African Americans, 164 Erythropoietin Early detection. See also Prevention Hematopoietic growth factors, 167 American Cancer Society National Conference on Esophageal cancer Cancer Prevention and Early Detection, 64 The National Cancer Data Base clinical Bladder cancer, 102 highlights, 189 Highlights of American Cancer Society National Nutrition, 413-414 Conference on Cancer Prevention and Early Estrogens Detection, 246-247 Malignant melanoma, 199-205 Breast cancer risk, 349-353 Breast cancer survivors, 355-358 Oral cancer, 126-127 (Letter) Hormone replacement therapy, 343-346 Ecologic studies Hormone replacement therapy risk, 365, 367, 370, 371 Occupational cancer, 81-82 Exogenous hormones Editorials Hormone replacement therapy risk, 366-368, 370 American Cancer Society Nutrition Guidelines, 323-324 (Guest Editorial) Cancer Statistics: A Measure of Progress, 3-4 F (Guest Editorial) Cancer Therapy — The 21st Century, 131-133 Familial colonic polyposis (Guest Editorial) Thyroid carcinoma, 265 Malignant Melanoma: Perspectives on Incidence and Fine-needle aspiration Its Effects on Awareness, Diagnosis, and Thyroid carcinoma, 270 Treatment, 195-198, (Guest Editorial) The Prevention of Occupational Cancer, 67-69 Follicular thyroid carcinoma. See also Thyroid carci- (Guest Editorial) noma Recent Advances in the Treatment of Thyroid Described, 262 Carcinoma, 258-260 (Guest Editorial) Molecular pathogenesis, 268-269 Electromagnetic field exposure, 29-44 Fungi Biologic activity, 30-31 Pulmonary complications, 309-311 Conclusions, 40-43 Electric and magnetic fields, 30 G Household appliances, 34-36 Occupational studies, 36-41 Overview, 29-30 Gardner’s syndrome Paternal occupation, 37-41 Thyroid carcinoma, 265 Residential studies, 31-34 Gastric cancer Endogenous hormones Cancer Statistics: A Measure of Progress, 3 (Guest Ed- Hormone replacement therapy risk, 366 itorial) Endometrial cancer Gastrointestinal cancer Hormone replacement therapy, 348-349 Hermone replacement therapy following, 358 Hormone replacement therapy risk, 370-371 Gene therapy Nutrition, 332 Systemic treatments, 135 Environmental carcinogens. See also Occupational Genetics cancer Bladder cancer, 94-95 Bladder cancer, 94 Highlights of American Cancer Society National Malignant melanoma, 205-212 Conference on Cancer “revention and Early Occupational cancer, 67 Detection, 247 Pesticides and herbicides, 336-337 Hormone replacement therapy risk, 368 Thyroid carcinoma, 259, 264-265 Nutrition, 336 CA—A CANCER JOURNAL FOR CLINICIANS SUBLEC Tr IN BEX, 1996: VOrE 46, NOS: 1-6 Thyroid carcinoma, 265 Hormone replacement therapy, 343-363 Wilms tumor, 47-48 Androgens, 347-348 Genitourinary malformation Breast cancer risk, 349-353 Wilms tumor, 47 Breast cancer survivors, 355-357 Endometrial cancer risk, 348-349 Graft failure Estrogens, 343-346 Bone marrow transplantation, 149-150 Gynecologic cancer survivors, 353-355 Graft-versus-host disease Indications, 358 Bone marrow transplantation, 144-145, 147, 148, Nongynecologic cancer survivors, 358 149, 150-151, 157 Overview, 343 Progestins, 346-347 Granulocyte colony-stimulating factor Regimens, 358 Hematopoietic growth factors, 166-167 Surveillance, 358 Growth factors. See also Hematopoietic growth factors Tamoxifen, 348 Cancer Therapy — The 21st Century, 132 Hormone replacement therapy risk, 365-373 (Guest Editorial) Breast cancer, 365-370 Hematopoietic growth factors, 165-184 Endometrial cancer, 370-371 Systemic treatments, 135 Overview, 365 Gynecologic cancer Household appliances Hormone replacement therapy following, 449-450 Electromagnetic field exposure, 34-36 Human immunodeficiency virus infection H Pulmonary complications, 311-312, 313 Hairy cell leukemia Systemic treatments, 135 Head and neck cancer Idiopathic pneumonia syndrome Systemic treatments, 135 Pulmonary complications, 318 Treatment, 127-128 (Letter) Immunotherapy. See also Malignant melanoma Heart Bladder cancer, 97, 98, 100-102 Estrogen replacement therapy, 343-344 Malignant melanoma, 225-244 Progestin replacement therapy, 346-347 Renal cell carcinoma, 291, 293-298 Wilms tumor, treatment sequelae, 57, 59 Immunotoxins Hematopoietic growth factors, 165-184 Systemic treatments, 135, 140 Breast cancer, metastatic, 174 Defined, 165 Interferon(s) Dose-intensity, 168-173 Systemic treatments, 135 Erythropoietin, 167 Interferon alpha Granulocyte colony-stimulating factor, 166-167 Bladder cancer, 101 Hematopoietic cell cycling, 174-175 Malignant melanoma, vaccine therapy, adjuvant Hematopoietic system, 165-166 therapy following surgical resection, 235-236 Hodgkin’s disease, 173 Renal cell carcinoma, 293-294, 295 Megakaryocyte growth factor, 167-168 Multiple myeloma, 174 Interleukin(s) Non-Hodgkin's lymphoma, 173-174 Systemic treatments, 135 Overview, 165 Interleukin-2 Supportive care/complications, 175-179 Bladder cancer, 101 Systemic treatments, 135 Malignant melanoma, vaccine therapy, 227 Hematuria Renal cell carcinoma, 294-295, 297 Bladder cancer, 94-95 Intravesical therapy Hepatic arterial infusion Bladder cancer, 97-100 Systemic treatments, 134 High-fat foods K Nutrition recommendations, 329-330 Hodgkin’s disease Keyhole-limpet hemocyanin Bone marrow transplantation, 155 Bladder cancer, 101 Hematopoietic growth factors, 173 Kidney. See also Renal cell carcinoma; Wilms tumor Hormonal therapy Renal cell carcinoma, 284-302 Renal cell carcinoma, 292-293 Wilms tumor, 46-63 VOL. 46 NO. 6 NOVEMBER/DECEMBER 1996 SEE PECT TR BEX. 195'65 VOL 46, L Marrow transplantation. See Bone marrow transplantation Laboratory evaluation Pulmonary complications, 304, 306 Medullary thyroid carcinoma. See also Thyroid Thyroid carcinoma, 270 carcinoma Wilms tumor, 51 Described, 265 Long-term follow-up, 278-279 Lentigo maligna melanoma, 200-201. See also Molecular pathogenesis, 268 Malignant melanoma Surgical management, 273 Leukemia Megakaryocyte growth and development factor Bone marrow transplantation, 152-154 Hematopoietic growth factors, 167-168 Cancer Therapy — The 21st Century, 132 (Guest Editorial) Melanoma. See Malignant melanoma Electromagnetic field exposure, 31, 34, 36, 37, 41, 42 Menopause. See also Hormone replacement therapy Hormone replacement therapy following, 358 Hormone replacement therapy, 343-363 Systemic treatments, 135 Metastatic disease Lifestyle Bladder cancer, 104-107 Highlights of American Cancer Society National Breast cancer, hematopoietic growth factors, 174 Conference on Cancer Prevention and Early Malignant melanoma, 200 Detection, 246 Prostate cancer, 252, 253 Nutrition, 338 Pulmonary complications, 313-314 Liver cancer Renal cell carcinoma, 284, 285, 286-287, 289, 290-298 Occupational cancer, 81 Thyroid carcinoma, 259, 262, 265, 274-277 Lung cancer Minority groups Cancer Statistics: A Measure of Progress, 4 African American statistics, 113-125, 164 (Errata) (Guest Editorial) Cancer statistics, 6 Cancer Therapy — The 21st Century, 132 Multiple myeloma (Guest Editorial) Bone marrow transplantation, 155 Hematopoietic growth factors, 168-169 Hematopoietic growth factors, 174 The National Cancer Data Base clinical highlights, 189 Mycobacteria Nutrition, 332 Pulmonary complications, 309 Occupational cancer, 81, 83, 84 Myelodysplastic syndrome The Prevention of Occupational Cancer, 68 Bone marrow transplantation, 153 (Guest Editorial) Systemic treatments, 135 Myeloid recovery Hematopoietic growth factors, 176-179 Lymphoepithelioma Bladder cancer, 93-94 Lymphokine-activated killer cell therapy Renal cell carcinoma, 296 The National Cancer Data Base clinical highlights, Lymphoma 185-192 Electromagnetic field exposure, 34 Breast cancer, 191 Hormone replacement therapy following, 358 Cervical cancer, 192 Systemic treatments, 135 Colorectal cancer, 190 Data sources, 185-186 Esophageal cancer, 189 Lung cancer, 189 Ovarian cancer, 190 Magnetic field exposure. See Electromagnetic field Overview, 185 exposure Pancreatic cancer, 188 Malignant melanoma, 199-216 Patient care evaluation, 186-187 Clinical images, 245 Prostate cancer, 188 Early detection, 199-205 Neck dissection Malignant Melanoma: Perspectives on Incidence Thyroid carcinoma, 274-277 and Its Effects on Awareness, Diagnosis, and Treatment, 195-198 (Guest Editorial) Neoplastic disorders Overview, 199 Pulmonary complications, 313-314 Primary prevention, 205-214 Neuroblastoma Surgical management, 217-224 Bone marrow transplantation, 155-156 Vaccine therapy, 225-244 Wilms tumor, 51 380 CA—A CANCER JOURNAL FOR CLINICIANS SUBRP ECT ER DEX. 1996: VOL 46. NOS Nicotine. See Tobacco Oo Non-Hodgkin’s lymphoma Obliterative bronchiolitis Bone marrow transplantation, 154-155 Pulmonary complications, 318 Cancer Therapy — The 21st Century, 132 (Guest Editorial) Obstructive airway disease Hematopoietic growth factors, 173-174 Pulmonary complications, 318 Nursing Occupational cancer, 70-92. See also American Cancer Society National Conference on Environmental carcinogens Cancer Nursing Research, 141 Asbestos-related cancer, 254-256 (Letter) American Cancer Society Scholarships in Bladder cancer, 93-94 Cancer Nursing, 28 Categories of carcinogenicity, 71-72 Chemotherapeutic agents, 77 Nutrition, 325-341 Clinical evaluation of exposures, 89-90 Alcoholic beverages, 330-332 Epidemiologic identification, 77, 80-81 American Cancer Socitety Nutrition Guidelines, Epidemiologic study issues, 85-89 323-324 (Guest Editorial) Epidemiologic study types, 81-85 Antioxidants, 333 Evaluation criteria for carcinogenicity, 72 Artificial sweeteners, 333 Exposure and controls, examples of, 72-77 Beta carotene, 333 Human carcinogens, identification of, 71 Bioengineered foods, 334 Overview, 70-71 Breast cancer, 332 The Prevention of Occupational Cancer, 67-69 Calcium, 334 (Guest Editorial) Carotenoids, 334 Cholesterol, 334 Occupational studies Coffee, 334 Electromagneftiiecl d exposure, 36-41 Colorectal cancer, 332 Wilms tumor, 47 Cooking methods, 334-335 Oral cancer Endometrial cancer, 332 Early detection, 126-127 (Letter) Fiber, 335 Nutrition, 332-333 Fish oils, 335 Fluorides, 335 Orthotopic bladder replacement Folic acid, 335 Bladder cancer, 103-104 Food additives, 335 Osteoporosis Garlic, 336 Estrogen replacement therapy, 344-346 Genetics, 336 Progestin replacement therapy, 347 High-fat food limitation, 320-330 Highlights of American Cancer Society National Ovarian cancer Conference on Cancer Prevention and Early The National Cancer Data Base clinical Detection, 246-247 highlights, 190 Importance of, Systemic treatments, 135 Irradiated foods, 336 Lung cancer, 332 a Nitrite-preserved meats, 336 Olestra, 336 Olive oil, 336 Pancreatic cancer The National Cancer Data Base clinical Pesticides and herbicides, 336-337 highlights, 188 Physical activity, 330 Papillary thyroid carcinoma. See also Thyroid Phytochemicals, 337 carcinoma Plant sources recommendation, 326-329 Described, 261-262 Prevention, 338-339 Long-term follow-up, 278 Prostate cancer, 333 Molecular pathogenesis, 266-269 Salt, 337 Recurrent, 279 Selenium, 337 Surgical management, 274 Soybeans, 337 Stomach cancer, 333 Peripheral blood stem cell transplantation. See also Supplements, 337 Bone marrow transplantation Tea, 337-338 Stem cell sources, 145-146 Vegetables Systemic treatments, 134 Vitamin A, 338 Photodynamic therapy Vitamin C, 338 Bladder cancer, 101 Vitamin E, 338 VOL. 46 NO. 6 NOVEMBER/DECEMBER 1996 SUBLECT TN DEX. 1996: VOL 46; Pregnancy Treatment modalities, 318-319 Breast cancer risk, 340-350 Tuberculosis, 308-309 Breast cancer survivors, 357 Viruses, 311 Hormone replacement therapy risk, 368-369 Pulmonary edema Prevention. See also Early detection Pulmonary complications, 314 American Cancer Society National Conference on Cancer Prevention and Early Detection, 64 Highlights of American Cancer Society National Conference on Cancer Prevention and Early Detection, 246-247 Radiation pneumonitis Nutrition, 338-339 Pulmonary complications, 317 Occupational cancer, 70-71 Radiation therapy The Prevention of Occupational Cancer, 67-69 Bladder cancer, 102-103 (Guest Editorial) Prostate cancer, 249-253 Primary cutaneous melanoma. See Malignant Renal cell carcinoma, 292 melanoma Thyroid carcinoma, 277-278 Wilms tumor, 53 Primary prevention. See also Prevention Malignant melanoma, 205-214 Radiology Bone marrow transplantation, 146 Progestins Occupational cancer, 73 Breast cancer risk, 353 Pulmonary complications, 303-304, 305, 308, 309 Hormone replacement therapy, 346-347 Renal cell carcinoma, 285 Hormone replacement therapy risk, 365 Thyroid carcinoma, 271 Prognosis Wilms tumor, 51-52, 58 Malignant melanoma, 217-218 Renal cell carcinoma, 284-302 Renal cell carcinoma, 285 Clinical presentation, 284-285 Thyroid carcinoma, 261-264 Diagnosis, 285-287 Prostate cancer Management of clinically localized, 287-290 The National Cancer Data Base clinical Management of locally invasive, 290 highlights, 188 Management of metastatic disease, 290-298 Nutrition, 333 Overview, 284 Staging and prognosis, 285 Prostate cancer management, 249-253 Complications, 252-253 RET proto-oncogene Future considerations, 253 Thyroid carcinoma, 265-268, 279 Overview, 249-250 Rhabdoid tumor of the kidney Panel conclusion, 250 Wilms tumor, 50, 52, 58 Panel recommendations, 250 Panel treatment recommendations, 250-252 Rhabdomyosarcoma Staging, 252 Bladder cancer, 93-94 Protozoans Pulmonary complications, 311-313 S Pulmonary complications, 303-320 Atypical (non-tuberculosis) mycobacteria, 309 Sarcomatoid carcinoma Bacterial pneumonia infections, 306-308 Bladder cancer, 93-94 Bone marrow transplantation, 317 Skeletal metastases Bronchiolitis obliterans with organizing pneumonia, 318 Clear cell sarcoma of the kidney, 50 Diagnosis, 303-306 Diffuse pulmonary hemorrhage, 317-318 Skin cancer. See Malignant melanoma Fungi, 309-311 Small-cell carcinoma Idiopathic pneumonia syndrome, 318 Bladder cancer, 93-94 Neoplastic disorders, 313-314 Obliterative bronchiolitis and obstructive airway Small-cell lung cancer disease, 318 Hematopoietic growth factors, 168-169 Overview, 303 Squamous cell carcinoma Pleural effusion, 314 Bladder cancer, 93-94 Protozoans, 311-313 Pulmonary drug toxicity, 315-317 Staging Pulmonary edema, 314 Malignant melanoma, surgical management, 217-218 Radiation pneumonitis, 317 Malignant melanoma, vaccine therapy, 225-226, Thromboembolic disease, 314-315 230-235 382 CA—A CANCER JOURNAL FOR CLINICIANS SUBJECT INDEX 1996 Prostate cancer, 25 The Prevention of Occupational Cancer, 68 Renal cell carcinoma, 285 (Guest Editorial) Thyroid carcinoma, 261-264 Total body irradiation Wilms tumor, 49, 53 Bone marrow transplantation, 146, 148 Steroid therapy Pulmonary complications, 312, 317 Toxins Bladder Cancer, 93-94 Stomach cancer Transitional cell carcinoma Nutrition, 333 Bladder cancer, 93-94 Sunlight Tuberculosis Malignant melanoma, 205-212 Pulmonary complications, 308-309 Surgical management Bladder cancer, 96-97, 102, 103-104, 108 Tumor-infiltrating lymphocyte cellular therapy Renal cell carcinoma, 296 Malignant melanoma, vaccine therapy, adjuvant therapy following, 230-240 Tumor necrosis factor Prostate cancer, 249-253 Systemic treatments, 135 Renal cell carcinoma, 287-292 Thyroid carcinoma, 272-277 Wilms tumor, 52-53 U Syngeneic marrow transplantation Ultrosonography Stem cell sources, 144 Thyroid carcinoma, 271 Systemic treatments, 134-141 Undifferentiated carcinoma Bladder cancer, 93-94 T Tamoxifen V Breast cancer survivors, 357 Hormone replacement therapy, 348 Vaccine therapy. See also Malignant melanoma Hormone replacement therapy risk, 367-368 Malignant melanoma, 225-244 Malignant melanoma, vaccine therapy, 233 Vegetables Taxol Nutrition, 326,327 Pulmonary complications, 316-317 Vinyl chloride Taxotere Occupational cancer, 81 Pulmonary complications, 316-317 Viruses Testicular cancer Pulmonary complications, 311 Bone marrow transplantation, 156 Vitamin supplements Thromboembolic disease Nutrition, 337 Pulmonary complications, 314-315 Vitamin therapy Thrombopoietin Bladder cancer, 101 Hematopoietic growth factors, 167-168 Thyroid carcinoma, 261-283 Ww Classification, staging, and prognosis, 261-264 Diagnosis, 269-272 Wilms tumor, 46-63 Molecular pathogenesis, 265-269 Bilateral, 56-57 Overview, 261 Chemotherapy, 53-56 Postoperative management, 277-279 Epidemiology, 46-47 Recent Advances in the Treatment of Thyroid Follow-up, 58, 59-60 Carcinoma, 258-260 (Guest Editorial) Genetics, 47-48 Risk factors, 264-265 Overview, 46 Surgical management, 272-277 Pathology, 48-50 Tobacco Presentation and evaluation, 50-52 Beta carotene, 333-334 Radiation therapy, 53 Bladder cancer, 94 Recurrent, 57 Cancer risk, 330-331 Staging, 53 Cancer statistics, 125 Surgical management, 52-53 Cancer Statistics: A Measure of Progress, 4 Treatment sequelae, 57, 59 (Guest Editorial) Workplace. See Occupational cancer VOL. 46 NO. 6 NOVEMBER/DECEMBER 1996 AUTHOR INDEX FSV: Vet £6... Ros.” 26 A sees L Appelbaum FR, 142-164 Lamm DL, 93-112 Armitage JO, 165-184 Landrigan PJ, 67-69 (Guest Editorial), 254-255 (Letter) Lenhard RE Jr, 3-4 (Guest Editorial), 323-324 (Guest Editorial) Barbo DM, 343-363 Lydiatt W, 128 (Letter) Barth A, 225-244 Beckwith JB, 46-63 Belldegrun A, 284-302 Bociek RG, 165-184 Marks R, 199-216 Boffetta P, 255-256 (Letter) Martin LM, 113-117 Bolden S, 5-7, 113-117 Mashberg A, 126-127 (Letter) Breslow NE, 46-63 McGinnis LS, 185-187 Menck HR, 185-187 Cc Middleton RG, 249-253 Morton DL, 225-244 Murphy GP, 185-187 Callendar DL, 261-283 Pp D’Angio GJ, 46-63 Parker SL, 5-7, 113-117 deKernion JB, 284-302 Se Rigel DS, 195-198 (Guest Editorial) Eyre H, 185-187 Ritchey ML, 46-63 Rosenthal DS, 131-133 (Guest Editorial) Runowicz CD, 365-373 FE S Figlin RA, 284-302 Fremgen A, 185-187 Samit A, 126-127 (Letter) Sarto GE, 343-363 G Shah JP, 128 (Letter) Smith HO, 343-363 Gagel RF, 261-283 Sokoloff MH, 284-302 Gerrits JF, 254 (Letter) Stellman JM, 70-92, 255-256 (Letter) Goepfert H, 261-283 Stellman SD, 70-92, 255-256 (Letter) Green DM, 46-63 Stover DE, 303-320 Grundy PE, 46-63 + H Thomas PRM, 46-63 Hawkins R, 255 (Letter) Tilashalski KR, 127 (Letter) Heath CW Jr, 29-44, 113-117 Tong T, 5-7, 113-117 Torti FM, 93-112 J U Jessup JM, 185-187 Urist MM, 217-224 K Ww ae Kammerer-Doak DN, 343-363 Kaner RJ, 303-320 Wells SA Jr, 258-260 (Guest Editorial) Krakoff TH, 134-141 Wilhelmsen NR, 126 (Letter) Winchester DP, 185-187 Wingo PA, 5-7, 113-117 CA—A CANCER JOURNAL FOR CLINICIANS